Product Description
CMN009 is an IL-18 armored anti-DLL3 CAR-CIK therapeutic for SCLC. (Sourced from: https://www.benzinga.com/pressreleases/23/06/n33020925/coimmune-obtains-license-to-target-dll3-with-il-18-armored-car-technology)
Mechanisms of Action: DLL3 Modulator
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: CoImmune
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 0: Small Cell Lung Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|